Trial Profile
Phase I study of HM12525A in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 05 Jun 2015 New trial record
- 03 Jun 2015 Results of this study will be presented at the American Diabetes Association's 75th Scientific Sessions, according to a Hanmi Pharmaceutical media release.